Scholars@Duke
Niharika Bansal Mettu

Niharika Bansal Mettu

Associate Professor of Medicine
Medicine, Medical Oncology
niharika.mettu@duke.edu
DUMC 3505, Durham, NC 27710
10 Bryan Searle Drive, Seeley G. Mudd Bldg, Room 433, Durham, NC 27710

Scholarly Works - Journal articles

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Journal article Clin Cancer Res · April 15, 2026 PURPOSE: The utility of combination treatment with gemcitabine and camonsertib, an ataxia telangiectasia and Rad3-related kinase inhibitor, in mediating tumor cell death was assessed in preclinical models, prompting clinical investigation. The phase Ib TRE ... Full text Link to item Cite

Safety and feasibility of talimogene laherparepvec in peritoneal surface malignancies: Results from the TEMPO trial.

Journal article Mol Ther Oncol · March 19, 2026 Peritoneal surface malignancies (PSMs) remain a therapeutic challenge, particularly in patients with unresectable disease who cannot benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The Talimogene Laherparepvec for the Trea ... Full text Link to item Cite

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies.

Journal article ESMO Open · July 2024 BACKGROUND: Pemigatinib is an oral, potent, selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor. FIGHT-101, a three-part, open-label, first-in-human, phase I/II study (NCT02393248), evaluated pemigatinib in patients with advanced solid tumors. ... Full text Link to item Cite

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib.

Journal article Clin Cancer Res · February 16, 2024 PURPOSE: Camonsertib is a highly selective and potent inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. Dose-dependent anemia is a class-related on-target adverse event often requiring dose modifications. Individual patient risk factors for ... Full text Link to item Cite

Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Journal article Journal of Clinical Oncology · January 1, 2024 Background: CTX-471, a fully human immunoglobulin G4 (IgG4) anti-CD137 agonist antibody, binds to a distinct epitope on CD137, and binds to the target with intermediate affinity which results in optimal agonism of the receptor and improved activation of T- ... Full text Cite

Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.

Journal article Cancer Res Commun · December 19, 2023 PURPOSE: This phase Ib open-label, multicenter, platform study (NCT02646748) explored safety, tolerability, and preliminary activity of itacitinib (Janus kinase 1 inhibitor) or parsaclisib (phosphatidylinositol 3-kinase δ inhibitor) in combination with pem ... Full text Link to item Cite

Exploratory analysis of mesenteric-portal axis CT radiomic features for survival prediction of patients with pancreatic ductal adenocarcinoma.

Journal article Eur Radiol · August 2023 OBJECTIVE: To develop and evaluate task-based radiomic features extracted from the mesenteric-portal axis for prediction of survival and response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Consecutive patients ... Full text Link to item Cite

Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis.

Journal article Sci Rep · November 9, 2022 Patients with non-small cell lung cancer (NSCLC) who have distant metastases have a poor prognosis. To determine which genomic factors of the primary tumor are associated with metastasis, we analyzed data from 759 patients originally diagnosed with stage I ... Full text Link to item Cite

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma.

Journal article Invest New Drugs · June 2021 Background Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We conducted a biomarker-dri ... Full text Link to item Cite

Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.

Journal article J Immunother Cancer · February 2020 BACKGROUND: The immunosuppressive desmoplastic stroma of pancreatic cancer represents a major hurdle to developing an effective immune response. Preclinical studies in pancreatic cancer have demonstrated promising anti-tumor activity with Bruton tyrosine k ... Full text Link to item Cite

Clinical Insights Into the Biology and Treatment of Pancreatic Cancer.

Journal article J Oncol Pract · January 2016 Pancreatic cancer is a devastating disease with a universally poor prognosis. In 2015, it is estimated that there will be 48,960 new cases of pancreatic cancer and that 40,560 people will die of the disease. The 5-year survival rate is 7.2% for all patient ... Full text Open Access Link to item Cite

Use of molecular biomarkers to inform adjuvant therapy for colon cancer.

Journal article Oncology (Williston Park) · August 2013 The decision about who may derive benefit from adjuvant chemotherapy in colon cancer is often a difficult one for clinicians. While multiple trials have demonstrated that adjuvant chemotherapy reduces the risk of recurrence and improves overall survival in ... Link to item Cite

Use of molecular biomarkers to inform adjuvant therapy for colon cancer

Journal article Oncology United States · January 1, 2013 The decision about who may derive benefit from adjuvant chemotherapy in colon cancer is often a difficult one for clinicians. While multiple trials have demonstrated that adjuvant chemotherapy reduces the risk of recurrence and improves overall survival in ... Cite

The nuclear receptor-coactivator interaction surface as a target for peptide antagonists of the peroxisome proliferator-activated receptors.

Journal article Mol Endocrinol · October 2007 The peroxisome proliferator-activated receptors (PPARalpha, PPARdelta, and PPARgamma) constitute a family of nuclear receptors that regulates metabolic processes involved in lipid and glucose homeostasis. Although generally considered to function as ligand ... Full text Link to item Cite